The Experts below are selected from a list of 228 Experts worldwide ranked by ideXlab platform
Ieva Saulite - One of the best experts on this subject based on the ideXlab platform.
-
Skin Test Reactivity to Hymenoptera Venom after Venom Immunotherapy Correlates Inversely with the IgG/IgE Ratio.
International archives of allergy and immunology, 2017Co-Authors: Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmid-grendelmeier, Martin GlatzAbstract:BACKGROUND: Skin Test Reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on Skin Test Reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in Skin Test Reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT. RESULTS: Fifty-four patients received ultrarush desensitization and subsequent VIT with wasp venom, 26 with honeybee venom, and 8 with both wasp and honeybee venom. Hymenoptera-specific Skin Test Reactivity decreased during VIT in most patients, and became negative in 8% of the wasp-allergic patients and in 25% of the honeybee-allergic patients. Serum levels of venom-specific IgE positively correlated to Skin Test Reactivity before VIT, but did not change significantly during VIT. IgG serum levels and the IgG/IgE ratio increased during VIT in most patients. A high IgG/IgE ratio correlated with low Skin Test Reactivity after ≥3 years of VIT. CONCLUSIONS: The correlation between a high venom-specific IgG/IgE ratio and low Skin Test Reactivity after VIT may be interesting for future investigations that assess its role as a potential marker for VIT efficacy.
-
Skin Test Reactivity to hymenoptera venom after venom immunotherapy correlates inversely with the igg ige ratio
International Archives of Allergy and Immunology, 2017Co-Authors: Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmidgrendelmeier, Martin GlatzAbstract:BACKGROUND: Skin Test Reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on Skin Test Reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in Skin Test Reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT. RESULTS: Fifty-four patients received ultrarush desensitization and subsequent VIT with wasp venom, 26 with honeybee venom, and 8 with both wasp and honeybee venom. Hymenoptera-specific Skin Test Reactivity decreased during VIT in most patients, and became negative in 8% of the wasp-allergic patients and in 25% of the honeybee-allergic patients. Serum levels of venom-specific IgE positively correlated to Skin Test Reactivity before VIT, but did not change significantly during VIT. IgG serum levels and the IgG/IgE ratio increased during VIT in most patients. A high IgG/IgE ratio correlated with low Skin Test Reactivity after ≥3 years of VIT. CONCLUSIONS: The correlation between a high venom-specific IgG/IgE ratio and low Skin Test Reactivity after VIT may be interesting for future investigations that assess its role as a potential marker for VIT efficacy.
Martin Glatz - One of the best experts on this subject based on the ideXlab platform.
-
Skin Test Reactivity to Hymenoptera Venom after Venom Immunotherapy Correlates Inversely with the IgG/IgE Ratio.
International archives of allergy and immunology, 2017Co-Authors: Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmid-grendelmeier, Martin GlatzAbstract:BACKGROUND: Skin Test Reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on Skin Test Reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in Skin Test Reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT. RESULTS: Fifty-four patients received ultrarush desensitization and subsequent VIT with wasp venom, 26 with honeybee venom, and 8 with both wasp and honeybee venom. Hymenoptera-specific Skin Test Reactivity decreased during VIT in most patients, and became negative in 8% of the wasp-allergic patients and in 25% of the honeybee-allergic patients. Serum levels of venom-specific IgE positively correlated to Skin Test Reactivity before VIT, but did not change significantly during VIT. IgG serum levels and the IgG/IgE ratio increased during VIT in most patients. A high IgG/IgE ratio correlated with low Skin Test Reactivity after ≥3 years of VIT. CONCLUSIONS: The correlation between a high venom-specific IgG/IgE ratio and low Skin Test Reactivity after VIT may be interesting for future investigations that assess its role as a potential marker for VIT efficacy.
-
Skin Test Reactivity to hymenoptera venom after venom immunotherapy correlates inversely with the igg ige ratio
International Archives of Allergy and Immunology, 2017Co-Authors: Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmidgrendelmeier, Martin GlatzAbstract:BACKGROUND: Skin Test Reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on Skin Test Reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in Skin Test Reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT. RESULTS: Fifty-four patients received ultrarush desensitization and subsequent VIT with wasp venom, 26 with honeybee venom, and 8 with both wasp and honeybee venom. Hymenoptera-specific Skin Test Reactivity decreased during VIT in most patients, and became negative in 8% of the wasp-allergic patients and in 25% of the honeybee-allergic patients. Serum levels of venom-specific IgE positively correlated to Skin Test Reactivity before VIT, but did not change significantly during VIT. IgG serum levels and the IgG/IgE ratio increased during VIT in most patients. A high IgG/IgE ratio correlated with low Skin Test Reactivity after ≥3 years of VIT. CONCLUSIONS: The correlation between a high venom-specific IgG/IgE ratio and low Skin Test Reactivity after VIT may be interesting for future investigations that assess its role as a potential marker for VIT efficacy.
Richard E. Chaisson - One of the best experts on this subject based on the ideXlab platform.
-
tuberculin Skin Test Reactivity anergy and hiv infection in hospitalized patients
The American Journal of Medicine, 1996Co-Authors: Eric M. Janis, David W. Allen, Marshall J. Glesby, Lisa A. Carey, Linda M. Mundy, Ramana Gopalan, Richard E. ChaissonAbstract:Purpose Detection of latent tuberculosis infection is an important step in the control of tuberculosis because high-risk persons may be given preventive therapy. The value of tuberculin Skin Testing in individuals with human immunodeficiency virus (HIV) infection, however, is limited by anergy. We evaluated the prevalence of tuberculin Skin Test Reactivity, anergy, and HIV infection in a group of hospitalized patients in an area where both tuberculosis and HIV infection are prevalent. Patients and methods Three hundred fifty-one patients consecutively admitted to a medical service of a large urban teaching hospital were enrolled in the study. All those with no documented history of a positive tuberculin Skin Test were evaluated on admission with purified protein derivative (PPD) by the Mantoux Test, and with anergy Testing using a multiple-puncture device. HIV Testing was offered to all patients who did not have a known history of HIV infection, and was performed when informed consent was obtained. Results Forty-one patients (12%) had a documented history of a positive PPD. Of the remaining 310 patients, 62 (20%) had a PPD response of ≥10 mm induration. Fifty-two (15%) of the 351 patients were HIV positive. None of the HIV-infected patients was PPD positive. Anergy was found in 63% of the HIV-infected patients and 28% of the HIV-seronegative patients. Independent risk factors for a positive PPD included age >55, male sex, and hypertension. HIV infection, current steroid use, and a history of cancer were associated with a negative PPD. Independent risk factors for anergy included HIV infection, current corticosteroid use, renal failure, pneumonia, and a history of cancer. Of the 62 new PPD-positive patients, 30 (48%) were candidates for chemoprophylaxis. Additionally, 30 (63%) of 48 HIV-seropositive patients who were completed Testing were anergic and might be candidates for chemoprophylaxis. Almost all of the patients eligible for chemoprophylactic therapy would have been detected if only patients at increased risk for developing tuberculosis were screened. Conclusions Tuberculosis infection, HIV infection, and anergy were common in patients admitted to this medical service. Interpretation of PPD Reactivity was confounded by a high prevalence of anergy, particularly in HIV-infected patients. A large proportion of patients Tested were candidates for chemoprophylaxis. Routine tuberculin Skin Testing with anergy Testing for high-risk patients on admission to the hospital is useful for identifying patients who might benefit from prophylaxis to help control the spread of tuberculosis.
-
Tuberculin Skin Test Reactivity, anergy, and HIV infection in hospitalized patients
The American journal of medicine, 1996Co-Authors: Eric M. Janis, David W. Allen, Marshall J. Glesby, Lisa A. Carey, Linda M. Mundy, Ramana Gopalan, Richard E. ChaissonAbstract:Detection of latent tuberculosis infection is an important step in the control of tuberculosis because high-risk persons may be given preventive therapy. The value of tuberculin Skin Testing in individuals with human immunodeficiency virus (HIV) infection, however, is limited by anergy. We evaluated the prevalence of tuberculin Skin Test Reactivity, anergy, and HIV infection in a group of hospitalized patients in an area where both tuberculosis and HIV infection are prevalent. Three hundred fifty-one patients consecutively admitted to a medical service of a large urban teaching hospital were enrolled in the study. All those with no documented history of a positive tuberculin Skin Test were evaluated on admission with purified protein derivative (PPD) by the Mantoux Test, and with anergy Testing using a multiple-puncture device. HIV Testing was offered to all patients who did not have a known history of HIV infection, and was performed when informed consent was obtained. Forty-one patients (12%) had a documented history of a positive PPD. Of the remaining 310 patients, 62 (20%) had a PPD response of > or = 10 mm induration. Fifty-two (15%) of the 351 patients were HIV positive. None of the HIV-infected patients was PPD positive. Anergy was found in 63% of the HIV-infected patients and 28% of the HIV-seronegative patients. Independent risk factors for a positive PPD included age > 55, male sex, and hypertension. HIV infection, current steroid use, and a history of cancer were associated with a negative PPD. Independent risk factors for anergy included HIV infection, current corticosteroid use, renal failure pneumonia, and a history of cancer. Of the 62 new PPD-positive patients, 30 (48%) were candidates for chemoprophylaxis. Additionally, 30 (63%) of 48 HIV-seropositive patients who were completed Testing were anergic and might be candidates for chemoprophylaxis. Almost all of the patients eligible for chemoprophylactic therapy would have been detected if only patients at increased risk for developing tuberculosis were screened. Tuberculosis infection, HIV infection, and anergy were common in patients admitted to this medical service. Interpretation of PPD Reactivity was confounded by a high prevalence of anergy, particularly in HIV-infected patients. A large proportion of patients Tested were candidates for chemoprophylaxis. Routine tuberculin Skin Testing with anergy Testing for high-risk patients on admission to the hospital is useful for identifying patients who might benefit from prophylaxis to help control the spread of tuberculosis.
-
Tuberculin Skin Test Reactivity among adults infected with human immunodeficiency virus
The Journal of infectious diseases, 1992Co-Authors: Michael P. Johnson, Jacqueline S. Coberly, H. Camile Clermont, Richard E. Chaisson, Homer Davis, Phyllis Losikoff, Andrea J. Ruff, Reginald Boulos, Neal A. HalseyAbstract:Infection with the human immunodeficiency virus type 1 (HIV-1) results in decreased cell-mediated immunity, which includes decreased delayed hypersensitivity to Skin Test antigens. HIV-1 seropositivity and Skin Test Reactivity to purified protein derivative (PPD) were determined among 2042 healthy Haitian adults with normal chest radiographs. Among HIV-1-seropositive individuals, 52.3% (146/279) had PPD reactions greater than or equal to 10 mm compared with 67.2% (1184/1763) of the seronegative adults (P less than .001). However, the percentage of HIV-1-seropositive individuals with PPD reactions greater than or equal to 5 mm was similar to the percentage of seronegative adults with PPD reactions greater than or equal to 10 mm (180/279 [64.5%] vs. 1184/1763 [67.2%]). Assuming that the rate of prior infection with Mycobacterium tuberculosis was similar for HIV-1-seronegative and -seropositive populations, these data provide support for the recent recommendations to use induration of greater than or equal to 5 mm as evidence of past infection with M. tuberculosis in HIV-1 seropositive adults.
Emmanuella Guenova - One of the best experts on this subject based on the ideXlab platform.
-
Skin Test Reactivity to Hymenoptera Venom after Venom Immunotherapy Correlates Inversely with the IgG/IgE Ratio.
International archives of allergy and immunology, 2017Co-Authors: Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmid-grendelmeier, Martin GlatzAbstract:BACKGROUND: Skin Test Reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on Skin Test Reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in Skin Test Reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT. RESULTS: Fifty-four patients received ultrarush desensitization and subsequent VIT with wasp venom, 26 with honeybee venom, and 8 with both wasp and honeybee venom. Hymenoptera-specific Skin Test Reactivity decreased during VIT in most patients, and became negative in 8% of the wasp-allergic patients and in 25% of the honeybee-allergic patients. Serum levels of venom-specific IgE positively correlated to Skin Test Reactivity before VIT, but did not change significantly during VIT. IgG serum levels and the IgG/IgE ratio increased during VIT in most patients. A high IgG/IgE ratio correlated with low Skin Test Reactivity after ≥3 years of VIT. CONCLUSIONS: The correlation between a high venom-specific IgG/IgE ratio and low Skin Test Reactivity after VIT may be interesting for future investigations that assess its role as a potential marker for VIT efficacy.
-
Skin Test Reactivity to hymenoptera venom after venom immunotherapy correlates inversely with the igg ige ratio
International Archives of Allergy and Immunology, 2017Co-Authors: Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmidgrendelmeier, Martin GlatzAbstract:BACKGROUND: Skin Test Reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on Skin Test Reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in Skin Test Reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT. RESULTS: Fifty-four patients received ultrarush desensitization and subsequent VIT with wasp venom, 26 with honeybee venom, and 8 with both wasp and honeybee venom. Hymenoptera-specific Skin Test Reactivity decreased during VIT in most patients, and became negative in 8% of the wasp-allergic patients and in 25% of the honeybee-allergic patients. Serum levels of venom-specific IgE positively correlated to Skin Test Reactivity before VIT, but did not change significantly during VIT. IgG serum levels and the IgG/IgE ratio increased during VIT in most patients. A high IgG/IgE ratio correlated with low Skin Test Reactivity after ≥3 years of VIT. CONCLUSIONS: The correlation between a high venom-specific IgG/IgE ratio and low Skin Test Reactivity after VIT may be interesting for future investigations that assess its role as a potential marker for VIT efficacy.
Wolfram Hoetzenecker - One of the best experts on this subject based on the ideXlab platform.
-
Skin Test Reactivity to Hymenoptera Venom after Venom Immunotherapy Correlates Inversely with the IgG/IgE Ratio.
International archives of allergy and immunology, 2017Co-Authors: Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmid-grendelmeier, Martin GlatzAbstract:BACKGROUND: Skin Test Reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on Skin Test Reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in Skin Test Reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT. RESULTS: Fifty-four patients received ultrarush desensitization and subsequent VIT with wasp venom, 26 with honeybee venom, and 8 with both wasp and honeybee venom. Hymenoptera-specific Skin Test Reactivity decreased during VIT in most patients, and became negative in 8% of the wasp-allergic patients and in 25% of the honeybee-allergic patients. Serum levels of venom-specific IgE positively correlated to Skin Test Reactivity before VIT, but did not change significantly during VIT. IgG serum levels and the IgG/IgE ratio increased during VIT in most patients. A high IgG/IgE ratio correlated with low Skin Test Reactivity after ≥3 years of VIT. CONCLUSIONS: The correlation between a high venom-specific IgG/IgE ratio and low Skin Test Reactivity after VIT may be interesting for future investigations that assess its role as a potential marker for VIT efficacy.
-
Skin Test Reactivity to hymenoptera venom after venom immunotherapy correlates inversely with the igg ige ratio
International Archives of Allergy and Immunology, 2017Co-Authors: Ieva Saulite, Wolfram Hoetzenecker, Emmanuella Guenova, Peter Schmidgrendelmeier, Martin GlatzAbstract:BACKGROUND: Skin Test Reactivity to hymenoptera venom and venom-specific IgE are important for diagnosing venom allergy and deciding on the appropriate allergen for venom immunotherapy (VIT). Longitudinal data on Skin Test Reactivity during VIT and their correlation with venom-specific immunoglobulin (Ig)E and IgG are scarce. METHODS: We retrospectively analyzed shifts in Skin Test Reactivity and serum levels of venom-specific IgE and IgG in patients allergic to hymenoptera venom before the initiation of VIT with ultrarush therapy and after ≥3 years of VIT. RESULTS: Fifty-four patients received ultrarush desensitization and subsequent VIT with wasp venom, 26 with honeybee venom, and 8 with both wasp and honeybee venom. Hymenoptera-specific Skin Test Reactivity decreased during VIT in most patients, and became negative in 8% of the wasp-allergic patients and in 25% of the honeybee-allergic patients. Serum levels of venom-specific IgE positively correlated to Skin Test Reactivity before VIT, but did not change significantly during VIT. IgG serum levels and the IgG/IgE ratio increased during VIT in most patients. A high IgG/IgE ratio correlated with low Skin Test Reactivity after ≥3 years of VIT. CONCLUSIONS: The correlation between a high venom-specific IgG/IgE ratio and low Skin Test Reactivity after VIT may be interesting for future investigations that assess its role as a potential marker for VIT efficacy.